Deepankar Chakroborty
MSc
Epidermal Growth Factor Receptor (EGFR), EGFR family; Receptor Tyrosine Kinases; Tyrosine Kinase inhibitors; Cancer; Cancer Biology; Bioinformatics; Functional Genomics; R statistical programming; Therapeutic resistance; High -throughput screen
I am a Doctoral student in the Turku Doctoral Programme of Molecular Medicine. I have a background in biotechnology and bioinformatics. Currently, I am pursuing my PhD under the joint supervision of Prof. Klaus Elenius and Dr. Laura Elo.
Efforts of functional characterization of cancer-associated somatic mutations in oncogenes have been largely incomprehensive because they do not encompass the large majority. I have developed a pipeline to analyze thousands of variants of an oncogenic kinase gene in a single assay, I call iSCREAM (in vitro SCReen for Activating Mutation). We are developing the iSCREAM workflow to preemptively identify and characterize on-target secondary mutations that can cause therapeutic resistance, and then subsequently identify therapies that would potentially work for those resistant mutations.
- Database of recurrent mutations, an unbiased web resource to browse recurrent mutations in cancers (2026)
- iScience
- (2025)
- Molecular Oncology
- (2024)
- Embo molecular medicineMolecular Cancer Therapeutics
- (2024)
- OncogeneJournal of Biological Chemistry
- (2022)
- Cancer Research CommunicationsScientific Reports
- Novel tools for identification of oncogenic driver mutations (2022) Chakroborty Deepankar
- Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases (2021)
- An unbiased in vitro screen for activating epidermal growth factor receptor mutations (2019)
- L1TD1 - a prognostic marker for colon cancer (2019)
- BMC Cancer
- Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin (2018)



